1997
A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome
Rasmusson A, Anderson G, Lynch K, McSwiggan-Hardin M, Scahill L, Mazure C, Goodman W, Price L, Cohen D, Leckman J. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biological Psychiatry 1997, 41: 117-121. PMID: 8988803, DOI: 10.1016/s0006-3223(96)00380-0.Peer-Reviewed Original ResearchPathogenesis of Tourette's Syndrome
Leckman J, Peterson B, Anderson G, Arnsten A, Pauls D, Cohen D. Pathogenesis of Tourette's Syndrome. Journal Of Child Psychology And Psychiatry 1997, 38: 119-142. PMID: 9232461, DOI: 10.1111/j.1469-7610.1997.tb01508.x.Peer-Reviewed Original Research
1996
Elevated cerebrospinal fluid corticotropin-releasing ractor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls
Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougle C, Cohen D. Elevated cerebrospinal fluid corticotropin-releasing ractor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Biological Psychiatry 1996, 39: 776-783. PMID: 8731518, DOI: 10.1016/0006-3223(95)00221-9.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing factorCSF corticotropin-releasing factorTourette syndromeObsessive-compulsive disorderNormal controlsCerebrospinal fluidPathobiology of TSOCD patientsMedication-free outpatientsCompulsive disorderLumbar cerebrospinal fluidNoradrenergic mechanismsHealthy controlsTS patientsObsessive-compulsive behaviorTic severityCardinal featuresClinical ratingsPatientsSyndromeRelated conditionsStandardized fashionNeurobiological mechanismsGroup differencesDisorders
1995
Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls
Leckman J, Goodman W, Anderson G, Riddle M, Chappell P, McSwiggan-Hardin M, McDougle C, Scahill L, Ort S, Pauls D, Cohen D, Price L. Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls. Neuropsychopharmacology 1995, 12: 73-86. PMID: 7766289, DOI: 10.1038/sj.npp.1380241.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTourette syndromeHealthy controlsOCD patientsTS patientsHomovanillic acidCerebrospinal fluidCerebrospinal fluid biogenic aminesMedication-free OCD patientsPathobiology of TSCSF HVA levelsCompulsive disorderLumbar cerebrospinal fluidConcentrations of tyrosineHVA levelsCSF norepinephrineNoradrenergic mechanismsSerotonergic mechanismsCSF MHPGSerotonergic systemHealthy subjectsHealthy volunteersNormal volunteersPatientsSyndromeCerebrospinal fluid biogenic amines in obsessive compulsive disorder, tourette's syndrome, and healthy controls
Leckman J, Goodman W, Anderson G, Riddle M, Chappell P, McSwiggan-Hardin M, McDougle C, Scahill L, Ort S, Pauls D, Cohen D, Price L. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, tourette's syndrome, and healthy controls. Neuropsychopharmacology 1995, 12: 73-86. DOI: 10.1016/0893-133x(94)00070-g.Peer-Reviewed Original ResearchObsessive-compulsive disorderTourette syndromeHealthy controlsOCD patientsTS patientsHomovanillic acidCerebrospinal fluidCerebrospinal fluid biogenic aminesMedication-free OCD patientsPathobiology of TSCSF HVA levelsCompulsive disorderLumbar cerebrospinal fluidConcentrations of tyrosineHVA levelsCSF norepinephrineNoradrenergic mechanismsSerotonergic mechanismsCSF MHPGSerotonergic systemHealthy subjectsHealthy volunteersNormal volunteersPatientsSyndrome
1994
Elevated Cerebrospinal Fluid Levels of Oxytocin in Obsessive-compulsive Disorder: Comparison With Tourette's Syndrome and Healthy Controls
Leckman J, Goodman W, North W, Chappell P, Price L, Pauls D, Anderson G, Riddle M, McSwiggan-Hardin M, McDougle C, Barr L, Cohen D. Elevated Cerebrospinal Fluid Levels of Oxytocin in Obsessive-compulsive Disorder: Comparison With Tourette's Syndrome and Healthy Controls. JAMA Psychiatry 1994, 51: 782-792. PMID: 7524462, DOI: 10.1001/archpsyc.1994.03950100030003.Peer-Reviewed Original ResearchConceptsCerebrospinal fluid levelsObsessive-compulsive disorderCSF oxytocin levelsTourette syndromeArginine vasopressinFamily historyFluid levelsElevated cerebrospinal fluid levelsTic-related obsessive-compulsive disorderOxytocin levelsSubgroup of patientsSubset of patientsElevated CSF levelsCentral arginine vasopressinSubtype of OCDCSF levelsFamily genetic dataHealthy controlsTic disordersForms of OCDPatientsRelated syndromesCurrent severitySyndromeFamily study data
1992
Brain Monoamines and Amino Acids in Gilles de la Tourette's Syndrome: A Preliminary Study of Subcortical Regions
Anderson G, Pollak E, CHATTERJEE D, Leckman J, Riddle M, Cohen D. Brain Monoamines and Amino Acids in Gilles de la Tourette's Syndrome: A Preliminary Study of Subcortical Regions. JAMA Psychiatry 1992, 49: 584-586. PMID: 1378261, DOI: 10.1001/archpsyc.1992.01820070078016.Peer-Reviewed Original ResearchConceptsGilles de la Tourette's syndromeLateral globus pallidusSubstantia nigra reticulataMedial globus pallidusLa Tourette's syndromeTourette syndromeGlobus pallidusSubthalamic nucleusSubcortical regionsTS groupMajor projection areaPossible pathophysiologic significanceLevels of monoaminesNeurotransmitter-related enzymesLow TS groupBrains of subjectsBrain monoaminesMonoamine metabolitesPathophysiologic significanceControl groupPostmortem tissueSyndromeBrainAvailable brainPallidus
1988
Plasma MHPG: Within- and across-day stability in children and adults with tourette's syndrome
Riddle M, Leckman J, Anderson G, Ort S, Hardin M, Stevenson J, Cohen D. Plasma MHPG: Within- and across-day stability in children and adults with tourette's syndrome. Biological Psychiatry 1988, 24: 391-398. PMID: 2457395, DOI: 10.1016/0006-3223(88)90175-8.Peer-Reviewed Original ResearchTourette's Syndrome: Clinical and Neurochemical Correlates
RIDDLE M, LECKMAN J, ANDERSON G, ORT S, HARDIN M, STEVENSON J, COHEN D. Tourette's Syndrome: Clinical and Neurochemical Correlates. Journal Of The American Academy Of Child & Adolescent Psychiatry 1988, 27: 409-412. PMID: 3182595, DOI: 10.1097/00004583-198807000-00004.Peer-Reviewed Original ResearchConceptsTourette Syndrome Global ScalePHVA levelsTourette syndromeTS patientsLower CSF HVA levelsPlasma homovanillic acid levelsSimple motor ticsHomovanillic acid levelsCSF HVA levelsSignificant inverse correlationHVA levelsMotor restlessnessMotor ticsPretreatment levelsTotal symptomsNeurochemical correlatesTreatment responsePlasma 3Control groupPatientsSyndromeAcid levelsInverse correlationSignificant correlationIndividual items
1987
Plasma-free homovanillic acid: Within- and across-day stability in children and adults with tourette's syndrome
Riddle M, Leckman J, Anderson G, Ort S, Hardin M, Stevenson J, Cohen D. Plasma-free homovanillic acid: Within- and across-day stability in children and adults with tourette's syndrome. Life Sciences 1987, 40: 2145-2151. PMID: 3473273, DOI: 10.1016/0024-3205(87)90004-x.Peer-Reviewed Original ResearchParotid Gland Salivary Secretion in Tourette's Syndrome and Attention Deficit Disorder: A Model System for the Study of Neurochemical Regulation
COHEN D, ORT S, CARUSO K, ANDERSON G, HUNT R, SHAYWITZ B, KREMENITZER M, LECKMAN J. Parotid Gland Salivary Secretion in Tourette's Syndrome and Attention Deficit Disorder: A Model System for the Study of Neurochemical Regulation. Journal Of The American Academy Of Child & Adolescent Psychiatry 1987, 26: 65-68. PMID: 3034852, DOI: 10.1097/00004583-198701000-00013.Peer-Reviewed Original ResearchConceptsAttention deficit disorderTourette syndromeSalivary amylase concentrationTS patientsAmylase concentrationSalivary secretionNeurochemical regulationReceptor functioningTreatment of TSDeficit disorderSalivary amylase secretionParotid gland secretionSingle dosesSalivary volumeClonidinePatientsAmylase secretionSyndromeADD patientsSalivary measuresSecretionTotal amylaseSalivary amylaseDisordersChildren
1986
Rebound Phenomena in Tourette's Syndrome After Abrupt Withdrawal of Clonidine: Behavioral, Cardiovascular, and Neurochemical Effects
Leckman J, Ort S, Caruso K, Anderson G, Riddle M, Cohen D. Rebound Phenomena in Tourette's Syndrome After Abrupt Withdrawal of Clonidine: Behavioral, Cardiovascular, and Neurochemical Effects. JAMA Psychiatry 1986, 43: 1168-1176. PMID: 3465278, DOI: 10.1001/archpsyc.1986.01800120054011.Peer-Reviewed Original ResearchConceptsTourette syndromeNeurochemical effectsAbrupt withdrawalWorsening of ticsClonidine therapyClonidine withdrawalClonidine's effectivenessAdrenergic mechanismsBlood pressureOpen trialTic symptomsUrinary excretionPlasma levelsMotor restlessnessHomovanillic acidClonidine hydrochlorideSyndromeWithdrawal periodPrewithdrawal levelsRebound phenomenonPatientsPulse rateClonidineWithdrawalNorepinephrineThe Pathogenesis of Tourette Syndrome
Leckman J, Cohen D, Price R, Riddle M, Minderaa R, Anderson G, Pauls D. The Pathogenesis of Tourette Syndrome. 1986, 257-272. DOI: 10.1007/978-1-4684-5038-5_14.Peer-Reviewed Original Research
1984
Parotid Salivary Response to Clonidine in Tourette's Syndrome: Indicator of Adrenergic Responsivity
SELINGER D, COHEN D, ORT S, ANDERSON G, CARUSO K, LECKMAN J. Parotid Salivary Response to Clonidine in Tourette's Syndrome: Indicator of Adrenergic Responsivity. Journal Of The American Academy Of Child & Adolescent Psychiatry 1984, 23: 392-398. PMID: 6205037, DOI: 10.1016/s0002-7138(09)60316-2.Peer-Reviewed Original ResearchConceptsDrug-free patientsSalivary volumeTS patientsTourette syndromeSingle doseAdrenergic receptorsLong-term clonidine treatmentAmylase secretionGood therapeutic responseYoung male patientParotid salivary responseAdrenergic responsivityClonidine treatmentSalivary amylase concentrationMale patientsTherapeutic responseNoradrenergic functioningAmylase concentrationPatientsClonidineParotid glandSyndromeSalivary responseT patientsTotal secretion
1982
Clinical neurochemistry of autism and associated disorders
Young J, Kavanagh M, Anderson G, Shaywitz B, Cohen D. Clinical neurochemistry of autism and associated disorders. Journal Of Autism And Developmental Disorders 1982, 12: 147-165. PMID: 6184361, DOI: 10.1007/bf01531305.Peer-Reviewed Original ResearchConceptsNorepinephrine metabolismNeurochemical methodsClinical neurochemistryClinical studiesNeurochemical studiesBehavioral deficitsBiochemical dysfunctionBrain functionAutistic syndromeInfantile autismLow levelsNew studiesAutismDysfunctionSerotoninSyndromeAutistic individualsSymptomsNeurochemistryBrainMajor obstacleAssessment of Brain Function in Clinical Pediatric Research: Behavioral and Biological Strategies
Young J, Cohen D, Shaywitz S, Caparulo B, Kavanagh M, Hunt R, Leckman J, Anderson G, Detlor J, Harcherik D, Shaywitz B. Assessment of Brain Function in Clinical Pediatric Research: Behavioral and Biological Strategies. Schizophrenia Bulletin 1982, 8: 205-235. PMID: 6180470, DOI: 10.1093/schbul/8.2.205.Peer-Reviewed Original ResearchConceptsBrain functionPharmacological challenge testsSerious neuropsychiatric disorderClinical pediatric researchClinical research methodsSpecific neuronal systemsAttention deficit disorderClinical syndromeMetabolic dysfunctionTourette syndromeChallenge testClinical protocolsNew treatmentsClinical disordersNeuropsychiatric disordersNeuronal systemsClinical researchPediatric researchSyndromeDeficit disorderBest treatmentDisordersNovel biological strategiesLanguage disordersChildren
1981
Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report
Young J, Cohen D, Hattox S, Kavanagh M, Anderson G, Shaywitz B, Maas J. Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report. Life Sciences 1981, 29: 1467-1475. PMID: 6946271, DOI: 10.1016/0024-3205(81)90012-6.Peer-Reviewed Original ResearchConceptsFree MHPGPlasma free MHPGTourette syndromeChallenge doseNeuroendocrine responsesDoses of clonidineSingle oral dosesClonidine administrationResponsive patientsGH responseOral dosesMaintenance treatmentThyroxine indexClonidineTS patientsPatientsMHPGSyndromeT patientsNeuropsychiatric patientsPilot studyPreliminary reportMetabolic responseFurther investigationDose